Cargando…
Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice
With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their eff...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629544/ https://www.ncbi.nlm.nih.gov/pubmed/36322572 http://dx.doi.org/10.1371/journal.pone.0272594 |
_version_ | 1784823417707429888 |
---|---|
author | Ganesan, Shyamala Acosta, Hugo Brigolin, Chris Orange, Kallista Trabbic, Kevin Chen, Charles Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Chuang, Ya-Shan Fattom, Ali Bitko, Vira |
author_facet | Ganesan, Shyamala Acosta, Hugo Brigolin, Chris Orange, Kallista Trabbic, Kevin Chen, Charles Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Chuang, Ya-Shan Fattom, Ali Bitko, Vira |
author_sort | Ganesan, Shyamala |
collection | PubMed |
description | With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their efficacy against SARS-CoV-2 infection of upper respiratory tract and transmission is at best temporary. Development of safe and efficacious vaccines that are able to induce robust mucosal and systemic immune responses are needed to control new variants. In this study, we have used our nanoemulsion adjuvant (NE01) to intranasally (IN) deliver stabilized spike protein (S-2P) to induce immunogenicity in mouse and hamster models. Data presented demonstrate the induction of robust immunity in mice resulting in 100% seroconversion and protection against SARS-CoV-2 in a hamster challenge model. There was a significant induction of mucosal immune responses as demonstrated by IgA- and IgG-producing memory B cells in the lungs of animals that received intranasal immunizations compared to an alum adjuvanted intramuscular vaccine. The efficacy of the S-2P/NE01 vaccine was also demonstrated in an intranasal hamster challenge model with SARS-CoV-2 and conferred significant protection against weight loss, lung pathology, and viral clearance from both upper and lower respiratory tract. Our findings demonstrate that intranasal NE01-adjuvanted vaccine promotes protective immunity against SARS-CoV-2 infection and disease through activation of three arms of immune system: humoral, cellular, and mucosal, suggesting that an intranasal SARS-CoV-2 vaccine may play a role in addressing a unique public health problem and unmet medical need. |
format | Online Article Text |
id | pubmed-9629544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-96295442022-11-03 Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice Ganesan, Shyamala Acosta, Hugo Brigolin, Chris Orange, Kallista Trabbic, Kevin Chen, Charles Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Chuang, Ya-Shan Fattom, Ali Bitko, Vira PLoS One Research Article With the rapid progress made in the development of vaccines to fight the SARS-CoV-2 pandemic, almost >90% of vaccine candidates under development and a 100% of the licensed vaccines are delivered intramuscularly (IM). While these vaccines are highly efficacious against COVID-19 disease, their efficacy against SARS-CoV-2 infection of upper respiratory tract and transmission is at best temporary. Development of safe and efficacious vaccines that are able to induce robust mucosal and systemic immune responses are needed to control new variants. In this study, we have used our nanoemulsion adjuvant (NE01) to intranasally (IN) deliver stabilized spike protein (S-2P) to induce immunogenicity in mouse and hamster models. Data presented demonstrate the induction of robust immunity in mice resulting in 100% seroconversion and protection against SARS-CoV-2 in a hamster challenge model. There was a significant induction of mucosal immune responses as demonstrated by IgA- and IgG-producing memory B cells in the lungs of animals that received intranasal immunizations compared to an alum adjuvanted intramuscular vaccine. The efficacy of the S-2P/NE01 vaccine was also demonstrated in an intranasal hamster challenge model with SARS-CoV-2 and conferred significant protection against weight loss, lung pathology, and viral clearance from both upper and lower respiratory tract. Our findings demonstrate that intranasal NE01-adjuvanted vaccine promotes protective immunity against SARS-CoV-2 infection and disease through activation of three arms of immune system: humoral, cellular, and mucosal, suggesting that an intranasal SARS-CoV-2 vaccine may play a role in addressing a unique public health problem and unmet medical need. Public Library of Science 2022-11-02 /pmc/articles/PMC9629544/ /pubmed/36322572 http://dx.doi.org/10.1371/journal.pone.0272594 Text en © 2022 Ganesan et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Ganesan, Shyamala Acosta, Hugo Brigolin, Chris Orange, Kallista Trabbic, Kevin Chen, Charles Lien, Chia-En Lin, Yi-Jiun Lin, Meei-Yun Chuang, Ya-Shan Fattom, Ali Bitko, Vira Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title | Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title_full | Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title_fullStr | Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title_full_unstemmed | Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title_short | Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
title_sort | intranasal nanoemulsion adjuvanted s-2p vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629544/ https://www.ncbi.nlm.nih.gov/pubmed/36322572 http://dx.doi.org/10.1371/journal.pone.0272594 |
work_keys_str_mv | AT ganesanshyamala intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT acostahugo intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT brigolinchris intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT orangekallista intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT trabbickevin intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT chencharles intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT lienchiaen intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT linyijiun intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT linmeeiyun intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT chuangyashan intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT fattomali intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice AT bitkovira intranasalnanoemulsionadjuvanteds2pvaccinedemonstratesprotectioninhamstersandinducessystemiccellmediatedandmucosalimmunityinmice |